Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | 9-ING-41 + Carboplatin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
9-ING-41 | 9 ING 41 | GSK-3beta Inhibitor 4 | 9-ING-41 is an ATP-competitive inhibitor that selectively blocks GSK-3beta, potentially leading to cell cycle arrest and apoptosis, and antitumor effects including inhibition of cell proliferation and tumor growth (PMID: 31894292, PMID: 29846250). | |
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05010629 | Phase II | 9-ING-41 + Carboplatin | 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma | Recruiting | USA | 0 |
NCT03678883 | Phase Ib/II | 9-ING-41 + Carboplatin + Paclitaxel 9-ING-41 + Irinotecan 9-ING-41 + Doxorubicin 9-ING-41 + Lomustine 9-ING-41 + Carboplatin 9-ING-41 + Gemcitabine + Nab-paclitaxel 9-ING-41 9-ING-41 + Gemcitabine | 9-ING-41 in Patients With Advanced Cancers | Recruiting | USA | ESP | 1 |
NCT04832438 | Phase II | 9-ING-41 + Carboplatin | 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma | Withdrawn | USA | 0 |